DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease

Phase 1

Completed

Conditions: Graft vs Host Disease

First Posted Date: 2005-08-29

Last Posted Date: 2013-06-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00136396

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

A Study in Adults With Untreated Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: prednisone
Drug: doxorubicin
Drug: vincristine
Drug: methotrexate
Drug: asparaginase
Drug: dexamethasone
Radiation: cranial radiation
Drug: leucovorin
Drug: cytarabine
Drug: hydrocortisone
Drug: 6-mercaptopurine (6-MP)
Drug: e. coli L-asparaginase

First Posted Date: 2005-08-29

Last Posted Date: 2024-04-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 100

Registration Number: NCT00136435

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇨🇦
Manitoba Blood & Marrow Transplant Program CancerCare Manitoba, Winnipeg, Manitoba, Canada

and more 9 locations

High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia

First Posted Date: 2005-08-29

Last Posted Date: 2011-03-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00136448

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplasia

First Posted Date: 2005-08-29

Last Posted Date: 2011-03-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00136422

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome

First Posted Date: 2005-08-29

Last Posted Date: 2011-03-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00136461

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)

Phase 2

Completed

Conditions: Myelofibrosis
Agnogenic Myeloid Metaplasia
Chronic Myelomonocytic Leukemia
Myeloid Metaplasia

Interventions: Drug: Imatinib mesylate

First Posted Date: 2005-08-29

Last Posted Date: 2016-12-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 34

Registration Number: NCT00136409

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-08-29

Last Posted Date: 2009-12-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 85

Registration Number: NCT00136487

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Faulkner Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

Amifostine for Head and Neck Irradiation in Lymphoma

Phase 2

Completed

Conditions: Lymphoma
Hodgkin's Disease
Non-Hodgkin's Lymphoma

Interventions: Drug: Amifostine
Radiation: Radiation Therapy

First Posted Date: 2005-08-29

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 75

Registration Number: NCT00136474

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Premarin

First Posted Date: 2005-08-25

Last Posted Date: 2011-06-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 48

Registration Number: NCT00134654

Locations: 🇺🇸
Dana-Farber Cancer Insitute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-08-25

Last Posted Date: 2009-12-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00134706

Locations: 🇺🇸
Lowell General Hospital, Lowell, Massachusetts, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Wentworth Douglass Hospital, Dover, New Hampshire, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy